SCHEMBL15428014

SCHEMBL15428014

CC1(C)OC(C)(C)c2cc(Br)c(Br)cc21

nearest known ligand 0.35

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
AHR P35869 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7843935 0.85 BCHE (0.37)
SCHEMBL15427993 0.84 POLB (0.33)
SCHEMBL23187863 0.76 RXRA (0.38)
SCHEMBL15829321 0.76 RXRA (0.38)
SCHEMBL7846347 0.75 AHR (0.34) AHR
SCHEMBL15428012 0.74 AHR (0.32) AHR
SCHEMBL3685579 0.73 AHR (0.33) AHR
SCHEMBL18135467 0.72 PGR (0.33)
SCHEMBL24701899 0.72 TDP1 (0.39)
SCHEMBL15415672 0.69 AHR (0.30) AHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11917901-B2 Metal complexes UDC IRELAND LIMITED (IE) 2024-02-27 US disclosed
US-11917901-B2 Metal complexes UDC IRELAND LIMITED (IE) 2024-02-27 US disclosed
US-11005050-B2 Metal complexes MERCK PATENT GMBH (DE) 2021-05-11 US disclosed
EP-3424936-B1 METAL COMPLEXES MERCK PATENT GMBH (DE) 2021-04-07 EP disclosed
EP-2935293-B1 IRIDIUM COMPLEXES AND THEIR USE IN ELECTRONIC DEVICES, ESPECIALLY ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2019-08-21 EP disclosed
EP-3069392-B1 COMPOUND WITH NOVEL SIX-MEMBERED RING STRUCTURE FOR USE IN ORGANIC ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2019-08-07 EP disclosed
US-10374167-B2 Compound with novel six-membered ring structure for use in organic electronic devices MERCK PATENT GMBH (DE) 2019-08-06 US disclosed
EP-3424936-A1 METAL COMPLEXES Merck Patent GmbH (DE) 2019-01-09 EP disclosed
US-9837622-B2 Metal complexes MERCK PATENT GMBH (DE) 2017-12-05 US disclosed
US-9837622-B2 Metal complexes MERCK PATENT GMBH (DE) 2017-12-05 US disclosed
US-20150318498-A1 Metal Complexes MERCK PATENT GMBH (DE) 2015-11-05 US disclosed
US-20150263297-A1 Metal Complexes MERCK PATENT GMBH (DE) 2015-09-17 US disclosed
US-20150263297-A1 Metal Complexes MERCK PATENT GMBH (DE) 2015-09-17 US disclosed
WO-2015117718-A1 METAL COMPLEXES MERCK PATENT GMBH (DE) 2015-08-13 WO disclosed
WO-2015104045-A1 METAL COMPLEXES MERCK PATENT GMBH (DE) 2015-07-16 WO disclosed
US-20150171348-A1 Metal Complexes MERCK PATENT GMBH (DE) 2015-06-18 US disclosed
US-20150171348-A1 Metal Complexes MERCK PATENT GMBH (DE) 2015-06-18 US disclosed
WO-2014094962-A2 METAL COMPLEXES MERCK PATENT GMBH (DE) 2014-06-26 WO disclosed
WO-2014023377-A2 METAL COMPLEXES MERCK PATENT GMBH (DE) 2014-02-13 WO disclosed
WO-2014008982-A1 METAL COMPLEXES MERCK PATENT GMBH (DE) 2014-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10374167-B2 Compound with novel six-membered ring structure for use in organic electronic devices OCIAD2, OCIAD1, NR1D2 AHR 901/4885
US-20150318498-A1 Metal Complexes SOD1, AP1M1, AP3M1 AHR 3359/4885
US-20150263297-A1 Metal Complexes SOD1, AP1M1, AP3M1 AHR 3359/4885
US-20150171348-A1 Metal Complexes SOD1, AP1M1, AP3M1 AHR 3359/4885
US-11005050-B2 Metal complexes SOD1, AP1M1, AP3M1 AHR 3359/4885
US-11917901-B2 Metal complexes MCOLN2, MCOLN1, AP1M1 AHR 4105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.